Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

477
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
477
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

730
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
730
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

984
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
984
Common Respiratory Disorders01:31

Common Respiratory Disorders

1.3K
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

467
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
467
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Repositioning of 3-(isoxazol-3-yl)thiazolidin-4-one-based compounds via Inverse Virtual Screening: discovery of new ERα inhibitors with in vitro activity in breast cancer models.

European journal of medicinal chemistry·2026
Same author

Targeting Copper in Cancer: Chelators to Counteract Cuproplasia and Ionophores to Promote Cuproptosis.

Journal of medicinal chemistry·2026
Same author

Synthesis and biological evaluation of novel carbazole derivatives as broad-spectrum antibacterial agents to fight antimicrobial resistance (AMR).

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

SGLT2 Inhibitors in Alzheimer's Disease: Biochemical Insights and Therapeutic Potential.

International journal of molecular sciences·2026
Same author

Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Identification of 2-Substituted-3-Hydroxy-2,3-Dihydroquinazolin-4(1H) Ones as Cell-Active Inhibitors of KDM4A Lysine Demethylase.

ChemMedChem·2026

Related Experiment Video

Updated: Jan 18, 2026

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

3.4K

Developing Type II F508del-CFTR correctors with a protective effect against respiratory viruses.

Francesca Barbieri1, Maria Grazia Martina1, Emanuela Pesce2

  • 1Dipartimento di Scienze degli Alimenti e del Farmaco (DipALIFAR), Università degli Studi di Parma, Viale delle Scienze, 27/A, 43124, Parma, Italy.

European Journal of Medicinal Chemistry
|September 10, 2025
PubMed
Summary

Novel compounds offer a dual approach for cystic fibrosis (CF) treatment by correcting the CFTR protein and inhibiting viral replication. This strategy aims to prevent pulmonary exacerbations in CF patients without resistance risk.

More Related Videos

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.1K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.0K

Related Experiment Videos

Last Updated: Jan 18, 2026

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

3.4K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.1K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.0K

Area of Science:

  • Biochemistry
  • Virology
  • Genetics

Background:

  • Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations, leading to mucus buildup and increased infection risk.
  • Pulmonary exacerbations (PEs) in CF are often triggered or worsened by respiratory viral infections, complicating disease management.
  • Current CF therapies focus on managing symptoms, highlighting the need for novel strategies targeting underlying causes and exacerbating factors.

Purpose of the Study:

  • To develop novel multitarget agents for cystic fibrosis (CF) that correct F508del-CFTR protein function and possess broad-spectrum antiviral activity.
  • To evaluate the efficacy of these agents in preclinical models, focusing on their potential to prevent viral-induced pulmonary exacerbations.
  • To identify lead compounds with favorable pharmacokinetic profiles for further therapeutic development.

Main Methods:

  • Synthesis and screening of novel multitarget agents combining CFTR modulation with PI4KB inhibition.
  • Assessment of F508del-CFTR correction in various cell models, including FRT, CFBE41o-, and primary human airway epithelial cells.
  • Evaluation of broad-spectrum antiviral activity against viruses from Picornaviridae, Flaviviridae, and Coronaviridae families.
  • In vitro preclinical pharmacokinetic profiling of promising candidate compounds.

Main Results:

  • The bithiazole compound 3b demonstrated significant F508del-CFTR correction in CF cell lines, both alone and in combination with other CFTR modulators.
  • Compound 3b exhibited broad-spectrum antiviral activity against key respiratory viruses at sub- to low-micromolar concentrations.
  • Further validation of CFTR correction was achieved in primary human airway epithelial cells, a critical model for CFTR rescue strategies.
  • Compound 3b displayed a favorable in vitro preclinical pharmacokinetic profile, indicating its potential for therapeutic use.

Conclusions:

  • Compound 3b represents a promising multitarget therapeutic candidate for cystic fibrosis (CF).
  • Its dual mechanism of action—CFTR correction and antiviral activity—offers a novel strategy to prevent pulmonary exacerbations.
  • These findings provide a strong basis for the development of simplified and effective CF therapies targeting both the genetic defect and infectious triggers.